Key facts
- Santersus’s last known valuation is $19.9M (Apr 2025).
- It has raised $8.3M; the latest was Later Stage VC ($6.4M) in Apr 2025.
- Notable investors include Norcliffe Capital, Terumo Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Santersus
- ·The full record, as it builds
Funding rounds
No funding rounds for Santersus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Santersus
Developer of a therapeutic apheresis device designed to capture and remove circulating nets from patient blood. The company's technology is used for the removal and cleansing of the blood of neutrophil extracellular traps and is connected to the plasma separation machine used to pump blood plasma, enabling the healthcare industry with a device for the treatment of patients in a variety of therapeutic areas through the selective extracorporeal removal of nets from blood.
- Sector
- Healthcare
- HQ
- Zürich, Switzerland
- Founded
- 2017
- Employees
- 7
- Website
- santersus.com/
- Ownership
- Privately Held (backing)
Santersus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Santersus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Santersus in its N-PORT filings yet. We sweep new filings monthly.